November 17, 2026Gymmaxxing

MK-677: Lean Mass, Water Weight and Strength

What MK-677 trial results do—and do not—show about lean mass, water weight and strength, with limits for interpreting physique claims.

MK-677 can raise fat-free mass in human studies, but that does not establish how much contractile muscle a younger lifter would gain. FDA's review distinguishes changes in growth hormone, IGF-1 and body composition from a demonstrated improvement in physical function. Those are different outcomes, and a result for one cannot substitute for another. FDA evidence review

What the often-cited trial measured#

Nass and colleagues studied healthy adults aged 60–81. The principal comparison was at one year; 65 participants completed that year. Participants were asked to maintain their usual diet and exercise rather than start a bodybuilding program.

Average one-year changeMK-677Placebo
Body weight+2.7 kg+0.8 kg
Fat-free mass by DXA (dual-energy X-ray absorptiometry)+1.1 kg−0.5 kg
Total body water+1.7 kg+0.1 kg

Compared with placebo, MK-677 did not significantly improve strength or physical function. The small study was not sufficient to settle functional benefits. The second year used a modified crossover: some participants changed treatment. It was not two uninterrupted years of the original comparison. Full trial

Was the gain all water?#

The trial does not support that simple conclusion. Extracellular water rose similarly in both groups; intracellular water differed. The authors interpreted the intracellular change as reflecting body cell mass. Water and fat-free mass overlap, so subtracting the water figure from the lean-mass figure does not calculate newly grown muscle. Trial body-water analysis

For a claim about “muscle gains,” first identify the measurement:

  • Scale weight: a change in total weight does not specify the tissue responsible.
  • DXA lean tissue: a scan estimate is not a direct weighing of muscle protein.
  • Strength: a tested performance outcome needs its own result.
  • Photographs: a visual change cannot establish its cause or identify how much tissue changed.

The useful response to a progress claim is to ask for the measurement, the comparison group and the time interval. Calling every lean-mass change muscle growth overstates the evidence; dismissing every change as meaningless fluid also goes beyond what was measured. Our body-composition tracking guide explains how to keep these outcomes separate.

Does the wider research establish a physique benefit?#

FDA's 2024 evaluation found insufficient evidence to establish ibutamoren's effectiveness for the nominated conditions, including sarcopenia, obesity and hip-fracture recovery. It highlighted small samples, short studies and missing or unproven clinically meaningful improvements. That assessment is not a trial of trained young adults, nor a prediction that every individual will respond identically. It does mean that a hormone increase alone is an inadequate basis for promising useful muscle or recovery results. FDA evaluation, conclusions

A study description also does not provide a validated personal dosing schedule. Neither an online before-and-after photograph nor an increased IGF-1 result supplies the missing controlled evidence.

What about safety?#

Ibutamoren is not FDA-approved. FDA's consumer warning lists fluid retention, altered glucose metabolism and insulin sensitivity, fatigue, muscle pain and possible heart-failure risk in some people. Long-term effects remain uncertain. FDA safety notice

The 2024 review also describes a hip-fracture trial stopped early after a congestive-heart-failure safety signal. Those patients differ from healthy lifters; the finding should neither be dismissed nor converted into a personal risk percentage. Research monitoring is not proof that self-directed use is safe. FDA safety review

Reading a product claim#

If you are comparing a claim with a paper, match the actual population, product, duration and measured outcome. A matching ingredient name does not establish that a vendor's capsule or solution is equivalent to the trial material.

The MK-677 reference page connects to existing supplier listings. Those listings include affiliate links, from which Biomogging may earn a commission. Their presence is not evidence of product quality, clinical equivalence or suitability for human use. Use the human-evidence checklist to examine the claim before treating a reported laboratory or scan change as a promised physique result.

Powered by BTST